Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$922.72K-$922.72KN/M vs Q3 2024 EPS Diluted-$0.03-$0.03N/M vs Q3 2024 Operating Income-$990,737N/M Operating Cash Flowderived-$1,133,924N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end